Led · Equity · Apr 2026

Osteoboost Health Inc. develops a wearable Class II prescription device worn around the hips that delivers low-magnitude vibration therapy to the lumbar spine and hips as a non-drug treatment for low bone density and osteopenia, particularly in postmenopausal women. The treatment approach is based on research originally funded by NASA and, in a double-blind trial at the University of Nebraska Medical Center, users who adhered to at least three 30-minute sessions per week for 12 months saw bone density loss reduced by 85% in the spine and 55% in the hips, per the company. The device received a Breakthrough Device designation in 2024 and was later cleared via the FDA De Novo pathway; the company began shipping in May. Since launch it has been prescribed by more than 2,500 physicians, including clinicians at over 30 academic medical centers. The company was also named to TIME’s 2025 list of Best Inventions. Osteoboost plans to use the new financing to scale manufacturing, expand clinical research, and broaden commercialization.

Led · Equity · Oct 2025

Smartlens’ flagship product, miLens, is the world’s first electronics-free soft contact lens capable of continuous intraocular pressure (IOP) measurement. The microfluidic lens pairs with the firm’s AI-powered smartphone imaging platform to capture real-time pressure data and deliver predictive analytics for glaucoma and ocular-hypertension patients. The company is running a multi-site U.S. pivotal trial and has advanced regulatory preparation, manufacturing scale-up, and clinical validation. Market demand appears strong: a Market Scope survey of 166 ophthalmic practitioners showed 96.2 % intend to adopt miLens once available. After securing FDA clearance, Smartlens plans an expedited commercial launch and expects its platform to enable earlier, data-driven interventions that could slow disease progression for the 180 million people affected by glaucoma and ocular hypertension worldwide. The recent $5.2 million bridge financing provides the capital needed to complete the clearance process and prepare for market entry.

Participated · Equity · Jul 2023

Wavely Diagnostics builds a smartphone-based diagnostic app that turns a phone into an acoustic tool to detect fluid in a child’s ear, enabling data-driven virtual pediatric ear infection care. The process is non-invasive, requires no additional hardware or special training, and is designed to give parents and providers reliable answers from home. The platform completed a phase I pilot and is currently in a phase II pilot with a leading U.S. health system. Wavely plans a broad public app store launch in late 2023 and intends to expand its diagnostics to enable nearly 70% of acute pediatric visits to shift to virtual care. Financially, the company has secured investor and grant funding totaling $6.35M to date, including a $1.8M Phase II SBIR grant for remote diagnostics awarded by the National Institute on Minority Health and Health Disparities. The company is currently offering the app to healthcare systems for pilots while preparing for wide-scale commercialization. Wavely Diagnostics is building smartphone-based digital diagnostics that turn a phone plus a paper funnel into a non-invasive acoustic tool for pediatric assessment, starting with ear infections. Its first product helps parents determine signs of possible ear infection and connects families to virtual physicians who can prescribe treatment. The app is designed to be user-friendly and requires no special hardware beyond a simple paper funnel. Wavely intends to expand the telehealth-integrated platform to offer additional virtual pediatric care solutions beyond ear infections. The company is preparing a commercial launch in spring 2022 and aims first at parents and at-home consumers, then at healthcare partners. Financially, Wavely has raised seed capital and received non-dilutive grant funding to advance product development.

Participated · Series A · May 2021

Astrocyte Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company based in Groton, Conn., focused on developing novel cerebroprotective therapeutics. Its lead candidate, AST-004, has shown efficacy across diverse small and large animal brain injury models and is being evaluated for a broad array of acute brain injuries including stroke and traumatic brain injury. Astrocyte is currently conducting Phase 1B clinical safety studies of AST-004 and is preparing for Phase 2 efficacy studies in 2024. The company is also assessing AST-004 in preclinical models of Alzheimer's disease to explore potential benefits in chronic neurodegenerative conditions. The announced financing will be used to accelerate clinical development of AST-004 and further preclinical assessment in Alzheimer's disease. Astrocyte positions its approach as a potential way to reduce astrocyte-induced excess inflammation and provide neuroprotection in combination and precision medicine strategies. Astrocyte Pharmaceuticals is advancing novel neuroprotective therapeutics intended to reduce brain injury from stroke, traumatic brain injury, concussion and other neurodegenerative conditions. Its lead therapeutic is based on technology licensed from the University of Texas Health Science Center at San Antonio. The company completed a Series A financing that raised $6 million. Proceeds from the round will be used to advance the lead program into Phase 1 human trials. Astrocyte describes itself as focused on addressing an unmet need for drugs that limit neurodegenerative brain injury. No operating metrics were disclosed in the article. Astrocyte Pharmaceuticals is a privately held drug development company focused on small‑molecule neuroprotective therapeutics for stroke, traumatic brain injury/concussion, and neurodegenerative disorders. The company is committed to proving the neuroprotective benefits of enhancing astrocyte function and advancing related therapeutic agents. Its lead program is AST‑004, which the company and investors cite as having promising preclinical efficacy and a novel mechanism of action. Astrocyte completed a Pre‑A financing that raised over $2.3M to support its development plans. The company intends to use proceeds to advance its first program into clinical studies. The press release also notes research support from the National Institute of Neurological Disorders and Stroke (NIH) and the Department of Defense under specific award numbers.